← Back to Clinical Trials
Recruiting NCT05855031

NCT05855031 The Liver Care Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05855031
Status Recruiting
Phase
Sponsor Zealand University Hospital
Condition Alcoholic Liver Disease
Study Type INTERVENTIONAL
Enrollment 408 participants
Start Date 2023-05-08
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 110 Years
Study Type INTERVENTIONAL
Interventions
Transient Elastography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 408 participants in total. It began in 2023-05-08 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units/week) throughout the last months, and assessed 6 months after randomization.

Eligibility Criteria

Inclusion Criteria: * Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde * Informed written consent Exclusion Criteria: * Not speaking Danish or English * Severe liver disease (known by the participant)

Contact & Investigator

Central Contact

Pernille Dahlin, MD

✉ pedah@regionsjaelland.dk

📞 +45 30291114

Principal Investigator

Gro Askgaard, PHD

PRINCIPAL INVESTIGATOR

Zealand University Hospital

Frequently Asked Questions

Who can join the NCT05855031 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Alcoholic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05855031 currently recruiting?

Yes, NCT05855031 is actively recruiting participants. Contact the research team at pedah@regionsjaelland.dk for enrollment information.

Where is the NCT05855031 trial being conducted?

This trial is being conducted at Køge, Denmark, Roskilde, Denmark.

Who is sponsoring the NCT05855031 clinical trial?

NCT05855031 is sponsored by Zealand University Hospital. The principal investigator is Gro Askgaard, PHD at Zealand University Hospital. The trial plans to enroll 408 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology